The STABLE study compared patients who took weekly tests compared with those who tested less regularly, and found that those who tested weekly had better results than those who did not.
The STABLE study was done to show how warfarin testing worked in a “real world” setting, according to Jack Ansell, MD, lead study investigator and professor of Medicine at Hofstra-North Shore/LIJ School of Medicine. The study compared patients who took weekly tests compared with those who tested less regularly, and found that those who tested weekly had better results than those who did not. In fact, Dr Ansell said, the results for patients testing weekly had better average time in therapeutic range (TTR) than found in most clinical trials. Read the article here.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More